CREBRF rs3738593: Obesity Risk and Diabetes Paradox
The CREBRF missense variant (commonly cataloged under rs3738593 or rs373863828) is a well-studied human genetic variant that leads to an amino acid substitution, p.Arg457Gln. Discovered primarily in Pacific Islander populations, this variant presents a remarkable biological paradox by being strongly associated with increased body mass index (BMI) while simultaneously conferring significant protection against type 2 diabetes. Cellular and metabolic studies suggest that this variant promotes efficient energy storage and cellular resilience, acting as a classic example of thrifty genetic architecture.
What each genotype means
Typical BMI and diabetes risk
This is the common genotype found in most global populations. It is associated with standard baseline expectations for body mass index and type 2 diabetes risk in the absence of the specific CREBRF variant.
This is the most common genotype globally, though it is less frequent in Polynesian populations where the A allele is prevalent.
Increased BMI, reduced diabetes risk
Carrying one copy of the A allele is associated with a higher body mass index and increased adiposity. Paradoxically, this genotype is also associated with a reduced risk of developing type 2 diabetes compared to those without the variant.
This genotype is common in Polynesian and Samoan populations, with frequencies often ranging between 15% and 25%, but it is extremely rare or absent in European and African populations.
Higher BMI, lower diabetes risk
Carrying two copies of the A allele is strongly associated with increased body mass index and higher lean mass. Research indicates this genotype is linked to a significantly lower risk of type 2 diabetes, suggesting a protective effect despite the higher BMI.
This genotype is found primarily in individuals of Polynesian ancestry and is extremely rare or absent in most other global populations.
Genetic Architecture and Location
The single nucleotide polymorphism cataloged as rs3738593 (often referenced in genetic literature and dbSNP as rs373863828) resides in the CREBRF gene on chromosome 5. This variant is a missense substitution involving a guanine-to-adenine transition (c.1370G>A) that alters codon 457, substituting a positively charged arginine residue with a neutral glutamine (p.Arg457Gln, historically described as p.Arg457Gln or p.Arg475Gln across different transcript isoforms). Because CREBRF is a protein-coding gene, this nonsynonymous change directly modifies the functional polypeptide chain. The genomic locus has been meticulously characterized in Oceanic cohorts, where it was pinpointed as the primary causal signal underlying large genome-wide association study peaks for metabolic phenotypes. While standard reference databases maintain cross-references for these accession numbers, the underlying molecular effect remains the same: a distinct structural modification in a conserved cellular regulatory factor.
Biological Function of the CREBRF Gene
The CREBRF gene encodes the CREB3 regulatory factor, a protein that acts as an essential intracellular regulator of cellular stress responses and transcriptional programs. CREBRF modulates the activity of CREB3-family basic leucine zipper transcription factors, which participate in the unfolded protein response within the endoplasmic reticulum, lipid metabolism, and survival during nutritional deprivation. Functional studies in adipocytes and metabolic cell lines demonstrate that the altered CREBRF protein promotes adipogenesis and fat accumulation while simultaneously reducing cellular energy consumption. Under conditions of nutrient starvation, cells expressing the variant allele exhibit enhanced survival and resistance to metabolic stress. This physiological profile fits the classic 'thrifty gene' hypothesis, wherein an allele that promotes lipid storage and reduces metabolic expenditure would have provided a profound evolutionary survival advantage to ancestral voyaging populations navigating long oceanic journeys.
The Metabolic Paradox: High BMI and Lower Diabetes Risk
Ordinarily, significant elevations in body mass index and adiposity correlate strongly with peripheral insulin resistance and an increased risk of developing type 2 diabetes. However, research into the CREBRF variant demonstrates a striking metabolic dissociation. Population studies led by international consortia have revealed that each copy of the minor allele increases BMI by roughly 1.3 to 1.6 kg/m², representing one of the largest single-variant effect sizes on human adiposity discovered to date. Paradoxically, despite this marked increase in body mass, carriers experience an estimated 30% to 40% reduction in the odds of developing type 2 diabetes per allele copy. Phenotyping studies suggest that the variant favors preferential storage of lipids in safe subcutaneous adipose depots rather than harmful ectopic sites like the liver, accompanied by preserved pancreatic beta-cell function and lower fasting glucose levels.
Population Frequency and Evolutionary Selection
The distribution of the CREBRF p.Arg457Gln variant is one of the most geographically differentiated in human genetics. The allele is found at notable frequencies across Polynesia and Micronesia, reaching approximately 15% to 26% in Samoan cohorts and ranging from 1% to 8% in indigenous Marianas and Micronesian populations from Guam and Saipan. In contrast, massive international sequencing efforts, including gnomAD and the 1000 Genomes Project, demonstrate that this variant is virtually absent or exceedingly rare across continental European, African, and East Asian populations. Population geneticists hypothesize that strong positive natural selection, combined with founder effects during the original settlement of the Pacific islands, drove this variant to its present high frequency, as efficient fat accumulation and metabolic economy conferred decisive survival advantages in historical times.
Clinical Interpretation and Practical Takeaways
Understanding a CREBRF genotype requires careful contextualization rather than clinical anxiety. Genotyping data cannot be used to diagnose a medical condition or predict an individual's future weight, as body composition is profoundly multifactorial and heavily shaped by dietary habits, physical activity, and social determinants of health. While harboring the variant is statistically associated with a higher baseline BMI, it does not imply inevitable metabolic dysfunction; in fact, carriers often maintain robust insulin sensitivity relative to their body weight. Commercial health risk algorithms calibrated exclusively on populations of European descent can misclassify Pacific Islanders carrying this allele as high risk for diabetes when their actual genetic risk is lower. Individuals reviewing genetic results should discuss personalized metabolic health with qualified healthcare providers rather than making unguided lifestyle or dietary changes.
How common is this variant?
The variant has a high allele frequency of approximately 15% to 26% in Polynesian populations such as Samoans, and between 1% and 8% across Micronesian groups. In stark contrast, it is virtually absent or exceptionally rare across continental European, African, and East Asian populations.
Frequently asked questions
What is the difference between rs3738593 and rs373863828?
Both identifiers refer to the same genetic missense change in the CREBRF gene, producing the p.Arg457Gln substitution. Research papers frequently use rs373863828 to report primary genome-wide findings, while rs3738593 serves as an overlapping or historical accession in genomic catalogs.
Does having this variant mean I will become obese?
No. While carrying the variant statistically shifts average body mass index upward by roughly 1.3 to 1.6 kg/m² per allele copy, it does not determine your destiny. Body weight is complex and heavily regulated by nutrition, energy balance, physical activity, and multiple environmental factors.
Why does a variant that raises BMI protect against diabetes?
Scientists believe the variant encourages the body to store excess energy safely in peripheral subcutaneous fat tissues and preserves lean mass, rather than accumulating toxic ectopic fat around internal organs like the liver and pancreas. This unique lipid distribution pattern helps maintain healthy insulin sensitivity.
Can I get tested for the CREBRF variant?
The variant is occasionally included on direct-to-consumer genotyping arrays or comprehensive clinical exome panels, particularly those serving Pacific Islander demographics. However, standard clinical care does not require testing for CREBRF, as routine metabolic management focuses on blood pressure, blood glucose, and lipid monitoring.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3738593?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29